StockNews.com Begins Coverage on Check-Cap (NASDAQ:CHEK)

Equities research analysts at StockNews.com initiated coverage on shares of Check-Cap (NASDAQ:CHEK) in a report released on Monday. The firm set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Performance

CHEK opened at $0.81 on Monday. The stock has a market capitalization of $4.73 million, a PE ratio of -0.27 and a beta of 0.39. Check-Cap has a one year low of $0.76 and a one year high of $3.45. The business’s 50 day moving average price is $1.24 and its 200 day moving average price is $1.76.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.